Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

THOMAS S GOULD

Allopathic & Osteopathic Physicians Pathology Anatomic Pathology & Clinical Pathology

NPI
1386671261
CMS profile
244027
Location
HOLYOKE, MA

General Payments · PY2018–2024

$208,814.42

  • Reported across 58 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$101,966.59

23 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $101,966.59 23

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Takeda Pharmaceuticals U.S.A., Inc. $101,966.59 23

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $280.86 4
PY2019 $283.74 6
PY2021 $9,566.66 3
PY2022 $61,749.93 14
PY2023 $34,966.64 8
PY2024 $101,966.59 23

Payment records · PY2024 (23)

Sorted by paying entity, then date · as published by CMS

Program year 2024 20182019202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
Takeda Pharmaceuticals U.S.A., Inc. $4,433.33 01/17/2024 Consulting Fee Undisputed 01/23/2026 1137560706 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,433.33 02/14/2024 Consulting Fee Undisputed 01/23/2026 1137560709 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,433.33 02/14/2024 Consulting Fee Undisputed 01/23/2026 1137560713 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,433.33 03/11/2024 Consulting Fee Undisputed 01/23/2026 1137560717 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,433.33 03/11/2024 Consulting Fee Undisputed 01/23/2026 1137560722 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,433.33 04/17/2024 Consulting Fee Undisputed 01/23/2026 1137560726 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,433.33 04/17/2024 Consulting Fee Undisputed 01/23/2026 1137560730 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,433.33 05/10/2024 Consulting Fee Undisputed 01/23/2026 1137560733 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,433.33 05/10/2024 Consulting Fee Undisputed 01/23/2026 1137560737 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,433.33 06/10/2024 Consulting Fee Undisputed 01/23/2026 1137560741 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,433.33 06/10/2024 Consulting Fee Undisputed 01/23/2026 1137560745 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,433.33 07/12/2024 Consulting Fee Undisputed 01/23/2026 1137560748 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,433.33 07/12/2024 Consulting Fee Undisputed 01/23/2026 1137560752 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,433.33 08/09/2024 Consulting Fee Undisputed 01/23/2026 1137560756 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,433.33 08/09/2024 Consulting Fee Undisputed 01/23/2026 1137560760 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,433.33 09/11/2024 Consulting Fee Undisputed 01/23/2026 1137560764 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,433.33 09/11/2024 Consulting Fee Undisputed 01/23/2026 1137560767 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,433.33 10/09/2024 Consulting Fee Undisputed 01/23/2026 1137560771 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,433.33 10/09/2024 Consulting Fee Undisputed 01/23/2026 1137560775 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,433.33 11/13/2024 Consulting Fee Undisputed 01/23/2026 1137560779 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,433.33 11/13/2024 Consulting Fee Undisputed 01/23/2026 1137560782 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,433.33 12/09/2024 Consulting Fee Undisputed 01/23/2026 1137560786 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,433.33 12/09/2024 Consulting Fee Undisputed 01/23/2026 1137560789 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.